Clene Inc. (NASDAQ: CLNN) Presents Updates on CNM-Au8(R) at

New Post Public Reply Private Reply Replies (0) Message Board
NetworkNewsWire
317
Clene Inc. (NASDAQ: CLNN) Presents Updates on CNM-Au8(R) at Emerging Growth Conference 73 – Biotech Feature

- CNM-Au8(R) works by improving cellular energy production and utilization, which is crucial for maintaining neuronal health
- Clene has conducted several clinical trials to evaluate the safety and efficacy of CNM-Au8 in neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”)
- The global ALS treatment market is expected to grow significantly, driven by the increasing prevalence of the disease among the aging population
- Clene has submitted a briefing book to the FDA to seek feedback on a potential pathway for accelerated approval for CNM-Au8 to treat ALS

Clene (NASDAQ: CLNN), a biopharmaceutical company, is at the forefront of transforming the treatment of neurodegenerative disorders like ALS (amyotrophic lateral sclerosis) and multiple sclerosis (“MS”). In a recent Emerging Growth Conference 73 – Biotech Feature, Clene presented new findings and information pertinent to current and potential investors.

Under the leadership of CEO Rob Etherington, the company focuses on improving mitochondrial health, which is crucial for neurological functions. Mitochondria play a vital role in cellular metabolism and energy production. In neurodegenerative diseases, impaired mitochondrial function is a significant issue. Clene’s lead agent, CNM-Au8, targets the nicotinamide adenine dinucleotide (NAD+) pathway to restore and protect neurological function.

CNM-Au8 works by improving cellular energy production and utilization, which is crucial for maintaining neuronal health. Mitochondrial dysfunction is a common pathway leading to neuronal death in neurodegenerative diseases. By targeting this dysfunction, CNM-Au8 aims to provide neuroprotection and promote remyelination, potentially altering the course of these debilitating conditions.

Clene has conducted extensive clinical trials to evaluate the safety and efficacy of CNM-Au8. In Phase 2 trials for ALS, the treatment has been associated with improved survival rates and delayed clinical worsening. The drug has demonstrated a a favorable safety profile, with over 650 years of cumulative patient exposure without any serious adverse events attributed to it. These trials have also demonstrated significant improvements in biomarkers and in measures of clinical function.

Key studies include:

HEALEY ALS Platform Trial with Harvard’s Massachusetts General Hospital: Focused on ALS, this study showed statistically significant survival benefits in the double-blind phase.

RESCUE-ALS Study: A nine-month double-blind study that continues to follow patients for over three years through an open-label long-term extension, demonstrating promising survival and functional preservation outcomes.

VISIONARY Multiple Sclerosis Study: Despite being half-enrolled due to the COVID pandemic, CNM-Au8 treatment on top of standard-of-care MS drugs showed significant improvements in vision and cognitive function, which are critical unmet needs in MS treatment.

The global ALS treatment market is expected to grow significantly, driven by the increasing prevalence of the disease among the aging population. CNM-Au8 holds promise not only for ALS but also for other neurodegenerative diseases like MS and Parkinson’s, where current treatment options are limited. Its ability to penetrate the blood-brain barrier and its neuroprotective properties make it a strong candidate for addressing the high unmet needs in these markets​.

With over 650 years of cumulative subject exposure, CNM-Au8 has shown a strong safety profile with no serious adverse events linked to the drug. This robust safety data coupled with efficacy and biomarker results from two independent Phase 2 clinical trials in ALS has been instrumental in the company’s engagement with the FDA. Clene has submitted a briefing book to the FDA to seek feedback on a potential pathway for accelerated approval for #CNMAU8.

Clene is gearing up for phase three programs for both ALS and MS. The company’s innovative approach, backed by strong intellectual property with over 150 patents worldwide, positions it as a leader in addressing neurodegenerative diseases. The anticipated FDA interactions and ongoing studies will be crucial steps towards potentially bringing a transformative treatment to patients suffering from these devastating conditions.

Clene’s commitment to improving mitochondrial health offers a beacon of hope for patients with neurodegenerative diseases. With its promising clinical data, strong safety profile, and strategic regulatory engagements, the company is well-positioned to make significant strides in this challenging field.

A replay of the presentation can be found on the Emerging Growth Conference YouTube channel (https://nnw.fm/369wU ).

For more information, visit the company’s website at www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://nnw.fm/CLNN

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer



Clene Inc. (CLNN) Stock Research Links

CLNN Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Charlotte's Top-Tier Home Sales Surge: A $15M Milestone

Updated Category News Views 53

Charlotte's Luxury Market: A Rapid Ascent Folks, buckle up, because the luxury home market in Charlotte isn't just on the rise—it's practically sky-high. Back in 2016, the idea of splashing out over $5 million on a house was almost unheard of in this neck of the woods. Only one brave soul did it at the time. Fast forward to this past year, and things are looking starkly...

Continue Reading
Gayatri Pariwar Celebrates 100 Years with Massive Yoga Event

Updated Category News Views 52

An Impressive Centenary for Gayatri Pariwar Sometimes, you get hit by a wave so big you can't ignore it, and Gayatri Pariwar's centennial festival in New Delhi was one such tsunami. Picture this: countless souls gathered to mark a hundred years of spiritual and social reform, not just with chants and talks, but through an awe-inspiring mass yoga event. In my decades...

Continue Reading
Scientific Games Joins NCPG’s 2026 Campaign Again

Updated Category News Views 39

Scientific Games Backs Responsible Gaming Again It's another year, and here's Scientific Games once more, guns blazing for a cause that's needed more than a few times over—responsible gambling. Those folks got their hearts in the right place, joining the National Council on Problem Gambling's 2026 Gift Responsibly campaign. Ninth time running, no less! It's like...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 569

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
191 Schools Honored for Academic Growth Success

Updated Category News Views 44

Celebrating Educational Progress Nationwide In a world where numbers fly off the stock tickers and translate into dollar signs in some corner office, it's refreshingly humbling to find real gains being celebrated in the educational sector. Curriculum Associates has tipped their hat to 191 schools that have done something remarkable: they've pushed students to stretch...

Continue Reading
ROBOTERA Debuts XHAND 1 Pro-U in NVIDIA Demo

Updated Category News Views 84

ROBOTERA Steps Up with XHAND 1 Pro-U Move over, traditional robotics; ROBOTERA is here to shake things up with their latest marvel, the XHAND 1 Pro-U. This futuristic gadget isn't just making waves at the Conference on Robot Learning (CoRL) where Jim Fan of NVIDIA spotlighted it in his GR00T 2 demo, it's setting a new bar for robotic dexterity. Hand in Glove with Human...

Continue Reading
Galileo's Robot Dog Takes Charge in Polish Warehouses

Updated Category News Views 146

Robotic Innovation Makes Waves in Europe You ever think you’d see the day when a dog—albeit a robotic one—takes the night shift at a warehouse? Well, here we are. Galileo Robotics has unleashed its C1-W robot dog in Poznan, Poland, and it's more than just a fancy tech gimmick. This thing's got potential, bridging gaps left wide open by human labor shortages and...

Continue Reading
Univers Partners to Propel Physical AI Across Industries

Updated Category News Views 113

Univers Sets Sights on Global Physical AI Expansion Now here's a tune we've been humming for a while—AI is coming to take over the mundane, and Univers seems to think it's got the right band together to make that a full-blown concert in the built environment. Announced right in the heart of Antalya, Türkiye, at the esteemed COP31, we're seeing Univers grab hands with...

Continue Reading
Elite Robots Expands Global Reach with Mobile Manipulators

Updated Category News Views 112

Robots Hitting the Road? Picture this: robots that aren't just bolted to a factory floor but roam the production lines like tireless workers on wheels. That's what Elite Robots is betting on with their shiny new ELITEMISSION mobile manipulators. Not Just Any Old Robot These bad boys combine a robotic arm with an autonomous mobile platform. Think of an octopus getting off...

Continue Reading
Mastering Prescription Labels: Critical Insights for Safety

Updated Category News Views 0

Revolutionizing How We Approach Prescription Labels Prescription labels aren't just scraps of paper or stickers slapped on bottles; they're lifelines. The insight from pharmacy expert Sheldon Birch could turn a regular label into a powerful tool for health management. According to Birch, the label is often disregarded yet speaks volumes about the medication you've got in...

Continue Reading

Top 5 Most Recently Viewed Articles

Ray Dalio Warns of Economic Heart Attack and Gold Investment

Updated Category News Views 330

Debt-Fueled Risks in the U.S. Economy Ray Dalio, founder of Bridgewater Associates, has recently shared his concerns regarding the growing debt burden facing the U.S. economy. According to Dalio, this financial strain resembles arterial blockage, leading to the possibility of a severe economic "heart attack." His warning speaks volumes as the national debt continues to...

Continue Reading
Citi Projects Stronger Global Economic Growth in 2024

Updated Category News Views 249

Global Economic Outlook for 2024 In a recent report, Citi's group of economists has expressed optimism about the global economic scene for 2024. They predict that the economy will exceed earlier expectations, thanks in part to lower interest rates and positive trends emerging from several markets. These elements create a more encouraging environment for growth compared to...

Continue Reading
Quarterhill Welcomes David Charron as CFO to Drive Growth

Updated Category News Views 226

David Charron Takes the Helm as Quarterhill's CFO Quarterhill Inc. (TSX: QTRH) is excited to announce that David Charron has been appointed as the new Chief Financial Officer (CFO). This strategic move comes as the company gears up for its next phase of growth. David brings over 15 years of experience in leadership roles within public technology companies, making him a...

Continue Reading
Autolus Therapeutics: Key Insights Ahead of Earnings Release

Updated Category News Views 209

Overview of Autolus Therapeutics Earnings Report Autolus Therapeutics (NASDAQ: AUTL) is preparing to share its quarterly earnings results soon. Investors are keenly anticipating this announcement, which will give them a clearer picture of the company’s performance and future direction. Forecasts and Market Expectations Analysts are projecting a loss per share (EPS) of...

Continue Reading
Blue Diamond Growers Earns Star Site Award for Safety Excellence

Updated Category News Views 299

Blue Diamond Growers Achieves Recognition for Safety Standards Blue Diamond Growers, the leading cooperative in almond marketing and processing, has reached a significant milestone by receiving the "Star Site" designation from Cal/OSHA. This recognition is awarded to employers who have excelled in managing safety and health programs effectively. Exceptional Safety at the...

Continue Reading